Amyloid Precursor Protein Secretases (beta-Secretase)

Endopeptidases that are specific for AMYLOID PROTEIN PRECURSOR. Three secretase subtypes referred to as alpha, beta, and gamma have been identified based upon the region of amyloid protein precursor they cleave.

Also Known As:

Networked: 1948 relevant articles (42 outcomes, 143 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Haass, Christian: 47 articles (07/2013 - 06/2002)
2.	Wolfe, Michael S: 37 articles (10/2015 - 04/2002)
3.	De Strooper, Bart: 36 articles (11/2015 - 04/2004)
4.	Steiner, Harald: 36 articles (03/2015 - 06/2002)
5.	Tomita, Taisuke: 31 articles (02/2015 - 04/2002)
6.	Iwatsubo, Takeshi: 28 articles (02/2015 - 04/2002)
7.	Li, Yue-Ming: 27 articles (08/2015 - 02/2002)
8.	Vassar, Robert: 25 articles (01/2015 - 12/2002)
9.	Golde, Todd E: 22 articles (01/2015 - 03/2002)
10.	Winblad, Bengt: 20 articles (09/2015 - 07/2003)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 08/01/2000 - "The latter is an important finding from the perspective of therapeutic treatment of Alzheimer's disease by targeting gamma-secretase processing of APP to reduce Abeta production." 12/18/2013 - "The antibody is probably therefore acting by steric hindrance of β-secretase and these data suggest that it will be effective in mice in vivo and could be an alternative potential therapy for Alzheimer's disease. " 02/01/2005 - "gamma-Secretase inhibitors are one promising approach to the development of a therapeutic for Alzheimer's disease (AD). " 01/01/2008 - "Gamma-secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimer's disease (AD). " 01/01/2008 - "Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective."
2.	Neoplasms (Cancer) 05/01/2011 - "These findings might have direct translational implications because different inhibitors of the γ-secretase complex are available and have yielded promising results in cancer trials." 08/01/2015 - "According to recent studies, γ-secretase inhibitors (GSIs), which function as Notch signaling inhibitors, could be used as therapeutic drugs in cancer. " 01/01/2013 - "In this study, we investigated the effects of Notch inhibition by γ-secretase inhibitor IX (GSI IX) in cultured human CC cell lines and we established a transgenic mouse model with liver specific expression of the intracellular domain of Notch (Notch-ICD) and inactivation of tumor suppressor p53. " 07/01/2012 - "Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors." 09/01/2007 - "In this study, we show that NOTCH signaling, as measured by the gamma-secretase cleavage product N(IC)-1, is active in both normal human and lung tumor samples; however, downstream NOTCH readouts (i.e., HES-1 and HES-5) are elevated in lung tumors. "
3.	Amyloid Plaque 12/01/2010 - "Interestingly, we observed a moderate, but significant, reduction in amyloid deposits in the forebrain of mice expressing S-palmitoylation-deficient γ-secretase subunits compared with mice overexpressing wild-type subunits, as well as a reduction in the levels of insoluble Aβ(40-42). " 03/21/2008 - "After inhibitor treatment, the improved memory function was accompanied by reduced amyloid plaque load, decreased Abeta40 and Abeta42, and reduced C-terminal beta-secretase fragment derived from APP by beta-secretase. " 12/01/2015 - "Additionally, we show that the impact that SEL-12 has on mitochondrial function is independent of its role in Notch signaling, γ-secretase proteolytic activity, and amyloid plaques. " 08/01/2014 - "Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures." 09/01/2013 - "The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques."
4.	Stroke (Strokes) 02/01/2014 - "Finally, mice treated with inhibitors of γ-secretase and HIF-1α exhibited improved outcome after focal ischemic stroke, with combined treatment being superior to individual treatments. " 07/01/2011 - "Treatment of mice with a γ-secretase inhibitor, compound E, reduced infarct size and improved functional outcome in a model of focal ischemic stroke. " 06/01/2006 - "Mice transgenic for antisense Notch and normal mice treated with inhibitors of the Notch-activating enzyme gamma-secretase showed reduced damage to brain cells and improved functional outcome in a model of focal ischemic stroke. " 10/24/2014 - "These results provide further support for the potential use of γ-secretase inhibitors as therapy for ischemic stroke. " 10/24/2014 - "However, the role of γ-secretase-mediated Notch signaling in activating MAPK following ischemic stroke has not been investigated. "
5.	Amyloidosis 04/01/2011 - "These data establish a functional role for 5-LO in the pathogenesis of AD-like amyloidosis, whereby it modulates the γ-secretase pathway. " 04/01/2008 - "These data establish for the first time a novel functional role for 5LO in the pathogenesis of AD-like amyloidosis, thereby modulating gamma-secretase activity. " 10/03/2007 - "Importantly, we demonstrate that there exists a critical gamma-secretase level that reduces the risk of amyloidosis in the CNS and limits tumorigenesis in epithelia. " 01/06/2010 - "Because the processing of APP to generate Abeta requires both gamma-secretase and BACE1, it is possible that moderate reductions of both enzymes would provide additive and significant protection against Abeta amyloidosis. " 11/15/2010 - "In vivo and in vitro studies show that the effect of this enzymatic pathway on amyloidosis is mediated by modulation of Aβ precursor protein processing via the β secretase (BACE) proteolytic cascade, which ultimately results in altered formation of Aβ peptides. "

Related Drugs and Biologics

1.	Amyloid (Amyloid Fibrils)
2.	Presenilins
3.	Proteins (Proteins, Gene)
4.	Folic Acid (Vitamin M)
5.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
6.	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamide
7.	Peptides
8.	N2- ((2S)- 2- (3,5- difluorophenyl)- 2- hydroxyethanoyl)- N1- ((7S)- 5- methyl- 6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- L- alaninamide
9.	2- (5,7- difluoro- 1,2,3,4- tetrahydronaphthalen- 3- ylamino)- N- (1- (2- methyl- 1- (neopentylamino)propan- 2- yl)- 1H- imidazol- 4- yl)pentanamide
10.	Cholesterol

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Cell Transplantation
3.	Immunotherapy
4.	Therapeutics
5.	Drug Therapy (Chemotherapy)